1. Keytruda's new subcutaneous formulation recommended for approval by European Medicines Agency. 2. This may enhance patient compliance and improve market positioning for MRK.
Approval of a new delivery method could significantly boost Keytruda sales, akin to historical boosts seen with new formulations in other therapies that led to increased patient uptake and accessibility.
The type of approval directly correlates with increased sales potential and market share for MRK's leading product.
The introduction of a new formulation typically leads to extended growth phases in revenue, as seen with other oncology drugs experiencing prolonged market presence and competitive advantage.